Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label pralsetinib versus standard care in RET-mutant medullary thyroid cancer
MOH_2022-06-20_011860Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pralsetinib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
pralsetinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on MOH_2022-06-20_011860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-20_011860.